• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GE HealthCare unveils next-generation SIGNA MRI technology, aiming to boost efficiency, enhance patient experience, and advance sustainability

    11/30/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email
    • SIGNA Bolt1, a new 3T MRI scanner, is designed with a next-gen gradient system engineered to support precision diagnostics, clinical efficiency, and advanced research capability.
    • SIGNA Sprint with Freelium,2 a new sealed magnet MRI system, seeks to reimagine 1.5T MRI by combining a sustainable design with remarkable image quality, and operational autonomy to expand access to MR.
    • Both new systems, 510(k) pending at the U.S. FDA, are powered by SIGNA One3, an ecosystem of AI-driven workflow solutions designed to reduce inefficiencies and support MRI exams from plan to scan and beyond.

    GE HealthCare (NASDAQ:GEHC) today announced the 510(k) submissions to the U.S. Food and Drug Administration (FDA) seeking clearance for next-generation SIGNA™ MRI technology. Unveiled at the Radiological Society of North America's 2025 Annual Meeting, these differentiated solutions are part of a wave of new GE HealthCare innovations aimed at tackling some of the most complex challenges in healthcare. Designed to enhance precision diagnosis for clinicians and help clinicians improve patient outcomes, the new technologies include GE HealthCare's4 1.5T MRI system, both equipped with an AI-powered workflow platform designed for end-to-end exam efficiency.

    With imaging needs outpacing the radiologist workforce5, leading to longer wait times, burnout and delays in diagnosis, many departments are struggling to keep pace. At the same time, aging equipment and flat reimbursement rates are pushing providers to seek smarter, more sustainable solutions.

    "The urgency for greater access, efficiency and precision in MRI has never been greater. We've listened to clinicians who are seeking smarter, more sustainable technologies to meet today's challenges and tomorrow's needs," said Kelly Londy, President & CEO, MR, GE HealthCare. "With the introduction of our advanced SIGNA lineup, we're delivering on a bold vision for MRI — one that intentionally puts smarter technology to work for clinicians and patients alike to make MRI more intuitive, more efficient, and more impactful in everyday care."

    SIGNA™ Bolt: Aiming to translate innovative discoveries and complex exams into everyday patient care

    SIGNA Bolt6 aims to bring to market our most advanced high-field, clinical wide bore 3.0T MRI system and is seeking to combine ultra-high gradient performance, intelligent digital radio frequency (RF) architecture, and sustainable design to deliver precision imaging, fast workflows, and seamless clinical-to-research flexibility, all with exceptionally low energy consumption and operational costs.

    SIGNA Bolt is designed to include:

    • The power needed to deliver diagnostic quality in everyday scans with outstanding gradient and RF performance for both research and clinical applications
    • Next-gen AI-enabled workflow of SIGNA One in combination with deep learning applications that are designed to enable accelerated examination times
    • Deep-learning based advanced applications that aim to enhance diagnostic capabilities
    • End-to-end clinical pathway solutions from planning to reporting for neurology and oncology
    • Advanced developer toolkits to simplify research

    SIGNA™ Sprint with Freelium™: Designed to be purposefully helium-free without compromising on clinical or operational efficiency

    SIGNA Sprint with Freelium7 aims to broaden access to sustainable and equitable MRI technology. With less than 1% helium usage8, Freelium is designed to provide effortless sustainability without compromising clinical and operational efficiency.

    Engineered for excellence, the SIGNA Sprint with Freelium 1.5T system is designed to support remarkable image quality through exceptional homogeneity, high signal-to-noise ratio (SNR) and image clarity. Integrated with deep learning solutions, including AIR™ Recon DL and Sonic DL with wide coverage of anatomies and clinical applications, the system aims to provide consistent clarity and diagnostic confidence.

    Designed with flexibility in mind, its Freelium ventless magnet is designed to allow installation virtually anywhere – from inside hospitals to remote regions, expanding access to advanced MR capabilities for more patients and communities. SIGNA Sprint with Freelium features two levels of operational autonomy to empower radiology departments: Scanning Autonomy with SIGNA One Interface, an intuitive user interface aiming to simplify scanning for all levels of technologist experience, and Autoramp with intelligent sensors designed to support automated magnet recovery and supporting system uptime without the need for a field engineer.

    SIGNA ™ Sprint with Freelium is designed to include:

    • A design that uses less than 1% helium versus conventional designs9 with no additional power or cooling required
    • MR magnet installation virtually anywhere – from inside hospitals to remote regions that need more access to advanced MR capabilities, due to its ventless design
    • Exceptional homogeneity10 designed for impressive image quality and diagnostic capability

    SIGNA One11: Aiming to reduce inefficiencies with a new, AI-powered MRI workflow platform

    A next-gen, AI-powered workflow platform that is designed to improve the imaging experience by combining precision with simplicity, SIGNA One offers five innovations at its core designed to streamline operations and elevate clinical confidence.

    "We're dedicated to making every interaction smooth, fast and patient centric by using predictive technology that boosts efficiency," said Bryan Mock, PhD, General Manager, Global Product Segment, Premium MR, GE HealthCare. "SIGNA One technology is designed to simplify and improve the efficiency of experienced users, while aiming to shorten the learning curve for new users. Regardless of a users' experience level, SIGNA One aims to liberate users from inefficiencies at every stage of the MR imaging process."

    SIGNA ™ One is designed to include12:

    • An intuitive user experience that may help reduce training time and aims to boost productivity while aiming to shorten the learning curve for new and less experienced users
    • The SIGNA One Table, designed to enhance patient comfort and simplify patient transport
    • Fully automated SIGNA One Camera with In-Room Console live feed, AI-enabled landmark localization and patient positioning verification, with real-time visual guidance on a touchscreen display — aiming to improve speed and accuracy of patient setup
    • Contactless respiratory and peripheral gating designed to capture physiological data effortlessly, regardless of patient orientation and without the need for external devices
    • High-resolution, In-Room Consoles empowering technologists with simple patient setup control, aiming to minimize interruptions and maximizing throughput

    GE HealthCare is integrating with NVIDIA technology to enhance the performance and intelligence of its MR products by utilizing NVIDIA GPUs to accelerate the development of deep learning reconstruction models. Accelerated by NVIDIA's RTX product line and programmed with the new SIGNA One MRI Workflow solutions and advanced deep learning tools that are designed to elevate the user and patient experience, SIGNA Bolt and SIGNA Sprint with Freelium are designed to provide powerful imaging techniques for tailored patient care.

    Learn more about these and other GE HealthCare MRI technologies at GE HealthCare's booth #7334 at RSNA's annual meeting in Chicago through Dec. 4.

    About GE HealthCare Technologies Inc.

    GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

    GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.

    Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

    1 SIGNA Bolt is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale.

    2 SIGNA Sprint with Freelium is a configuration of SIGNA Sprint Select. SIGNA Sprint Select is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale.

    3 SIGNA One is 510(k) pending with the U.S. FDA. Not CE marked. Not available for sale.

    4 Helium-free: Helium is permanently enclosed in the magnet.

    5 Harvey L. Neiman Health Policy Institute, 2025.

    6 SIGNA Bolt is 510(k) pending at U.S. FDA. Not CE marked, not available for sale.

    7 SIGNA Sprint with Freelium is a sealed configuration of SIGNA Sprint Select, 510(k) pending at the U.S. FDA. Not CE marked, not available for sale.

    8 Compared to conventional magnets.

    9 Helium-free: Helium is permanently enclosed in the magnet

    10 as conventional IPM magnet.

    11 SIGNA One represents features of SIGNA Bolt and SIGNA Sprint Select which are 510(k) pending at U.S. FDA. Not yet CE marked. Not available for sale.

    12 All features may not be included in all system configurations.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251128574510/en/

    GE HealthCare Media Contact:

    Katie Scrivano

    M +1 262-215-5281

    [email protected]

    Get the next $GEHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    10/13/2025$86.00Equal Weight
    Barclays
    10/7/2025$83.00Buy → Neutral
    Citigroup
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    9/9/2024$90.00Neutral
    JP Morgan
    More analyst ratings

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Imaging Rott Roland covered exercise/tax liability with 4,620 shares and exercised 5,341 shares at a strike of $55.91, increasing direct ownership by 3% to 29,122 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/12/25 4:05:10 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Chief Enterprise Oper. Officer Stacherski Kenneth R. covered exercise/tax liability with 892 shares, decreasing direct ownership by 2% to 40,996 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:19:36 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Chief People Officer Holton Adam Y covered exercise/tax liability with 464 shares, decreasing direct ownership by 3% to 16,768 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:18:39 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    SEC Filings

    View All

    SEC Form 144 filed by GE HealthCare Technologies Inc.

    144 - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/24/25 4:24:06 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SCHEDULE 13G filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/13/25 10:29:34 AM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form 10-Q filed by GE HealthCare Technologies Inc.

    10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)

    10/29/25 6:26:50 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on GE HealthCare with a new price target

    Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00

    10/13/25 8:53:16 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare downgraded by Citigroup with a new price target

    Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00

    10/7/25 8:57:17 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare upgraded by UBS with a new price target

    UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

    5/5/25 8:34:55 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025

    The company will showcase a wave of transformative innovations designed to address the most pressing challenges in healthcare, spanning the care journey across smart devices and drugs throughout disease states enabled by cloud and AI solutions. GE HealthCare has invested more than $3B in R&D since 2022, delivering an innovation renaissance across disease states to advance precision care. At this year's Radiological Society of North America's (RSNA) 2025 Annual Meeting, GE HealthCare (NASDAQ:GEHC) will showcase a wave of significant innovations grounded by its legacy and deep, global commitment to advancing precision care. For more than a century, GE HealthCare has stood at the intersec

    11/30/25 10:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare unveils next-generation SIGNA MRI technology, aiming to boost efficiency, enhance patient experience, and advance sustainability

    SIGNA Bolt1, a new 3T MRI scanner, is designed with a next-gen gradient system engineered to support precision diagnostics, clinical efficiency, and advanced research capability. SIGNA Sprint with Freelium,2 a new sealed magnet MRI system, seeks to reimagine 1.5T MRI by combining a sustainable design with remarkable image quality, and operational autonomy to expand access to MR. Both new systems, 510(k) pending at the U.S. FDA, are powered by SIGNA One3, an ecosystem of AI-driven workflow solutions designed to reduce inefficiencies and support MRI exams from plan to scan and beyond. GE HealthCare (NASDAQ:GEHC) today announced the 510(k) submissions to the U.S. Food and Drug Administr

    11/30/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare unveils Pristina Recon DL for mammography – deep learning image reconstruction technology delivering clearer image quality

    GE HealthCare has received FDA Premarket Authorization for Pristina Recon DL, an innovative 3D mammography reconstruction application. Powered by artificial intelligence (AI), Pristina Recon DL delivers sharper images with fewer artifacts, enhanced details, and greater consistency1 – helping clinicians make more confident diagnoses.  GE HealthCare (NASDAQ:GEHC) announced today that it has received FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology. Powered by deep learning, Pristina Recon DL sets a new standard in image definition and sharpness. Breast cancer remains one of the most common cancers among women, with one in eigh

    11/26/25 7:59:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/2/24 6:00:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    View All

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

    GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

    4/9/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare's MIM Software collaborates with Elekta to help enhance radiation therapy treatments and improve patient outcomes

    Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

    4/22/24 7:07:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Financials

    Live finance-specific insights

    View All

    GE HealthCare announces cash dividend for fourth quarter of 2025

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for mo

    11/24/25 5:15:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare reports third quarter 2025 financial results

    Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S. Organic orders growth was 6% with growth across all segments Net income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8% Diluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07 Cash flow from operating activities was $593 million; Free cash flow* was $483 million Excluding tariff impacts, margin and EPS would have exceeded prior year Raises the lower end of full-year 2025 Adjusted EPS* guidance range and reaffirms all other metrics GE HealthCare (NASDAQ:GEHC) today reported fina

    10/29/25 6:20:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare to announce third quarter 2025 results on October 29, 2025

    GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical te

    10/1/25 8:30:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    10/22/24 4:16:16 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    4/2/24 4:07:29 PM ET
    $GEHC
    Medical Electronics
    Health Care